The short version
Eli Lilly (LLY) reported on Thursday and raised its guidance sharply. Revenue of $24.4 billion, up 39%.
Here is the split that makes this quarter worth reading. Lilly's own release says the growth was driven by a 53% increase in volume, partially offset by a 15% decrease in realised prices.
It sold far more medicine, at meaningfully lower prices, and still grew 39%.
The two products doing the work:
- 💉 Mounjaro: up 65% to $10.7 billion
- 💉 Zepbound: up 48% to $5.4 billion
Guidance went up by $5.5 billion. Full-year revenue is now guided to $91-92 billion, from $85-87 billion, with a midpoint above the roughly $88.7 billion analysts expected. Shares rose more than 4% before the open.
One note before you read on: this is an article about a company's financial results. It is not medical advice, and nothing here is a view on any treatment. Anyone with questions about medication should speak to their own doctor.
People are searching:
- "Eli Lilly earnings"
- "LLY stock"
- "Mounjaro sales"
- "Zepbound revenue"
- "Eli Lilly guidance 2026"
- "weight loss drug stocks"
- "GLP-1 market"
- "volume vs price growth"
Explore global stocks and ETFs from $1 on Nemo.money — zero commission, and uninvested cash earns 6% AER interest, paid daily in USD.
What Lilly reported
- 💵 Revenue: $24.4 billion, up 39%, against roughly $22.4 billion expected.
- 📊 Adjusted earnings: $7.48 a share, comfortably ahead of consensus.
- 📈 Volume up 53%, realised prices down 15%.
- 💉 Mounjaro: $10.7 billion, up 65%.
- 💉 Zepbound: $5.4 billion, up 48%.
- 🧪 Key products: $17.1 billion, with immunology, oncology and neuroscience products doubling.
- 📐 Gross margin: 83.9%, up a percentage point.
Guidance rose substantially: full-year revenue to $91-92 billion from $85-87 billion, a $5.5 billion increase with a midpoint above consensus.
Two honest caveats on the quarter, both from the company:
- 💰 About $900 million of the revenue came from one-off benefits, mostly $410 million of Jardiance milestones plus favourable adjustments to rebate and discount estimates. Strip those out and the quarter is still excellent, but it is not all underlying demand.
- 📉 Earnings guidance moved differently from revenue. The underlying improvement of $4.07 a share at the midpoint was more than offset by $4.57 of acquired research charges from recent acquisitions, leaving EPS guidance at $35.00-36.00.
Why falling prices are the interesting part
Most companies grow revenue by charging more. Lilly grew 39% while charging 15% less.
That combination is rare, and it is the strongest version of growth there is:
- 📦 Volume up 53% means far more people are using these medicines. Demand is expanding, not just being monetised.
- 💲 Prices down 15% means that growth survived a significant price decline rather than depending on one.
- 🏭 Margins still expanded, to 83.9%, which says the company is producing more efficiently as it scales.
Why prices are falling matters too. Lilly has pointed to pressures including rebates and discounts, government pricing arrangements and listing agreements in markets such as China. Lower realised prices are partly a consequence of reaching more people through more channels, which is the trade-off behind the volume figure.
And competition is the other half of it. We wrote about the obesity-pill war between Lilly and Novo Nordisk when both brought oral treatments to market, and about how this category became one of the decade's biggest investing themes. Two large companies competing hard in one market is exactly the condition that produces falling prices and rising volumes at the same time.
Six companies, one question, six answers
This is the single most useful habit we have written about this month: when revenue rises, find out whether the company sold more or simply charged more.
We have now run the test on six businesses, and no two answers were the same:
- 💊 Eli Lilly: volume +53%, prices -15%, revenue +39%. Growth despite falling prices. The strongest version.
- 🥤 Coca-Cola: volumes +5% worldwide, price contributing just 1 point of 7% organic growth — almost all real demand, but North America was flat.
- 🍫 Nestlé India: volume growth across every category — demand genuinely expanding.
- 🧺 P&G: 2.4% volume growth inside 4% sales growth — people bought more, not just paid more.
- 💾 SanDisk: revenue +175% on mid-teens volume growth — almost entirely price, which is why the cycle question dominates.
- 💻 Infosys: AI revenue +29% in a quarter, total revenue +1.2% — one part growing, the rest shrinking.
Read the list again and the hierarchy becomes obvious. Growing on volume while prices fall is the most durable. Growing on volume with stable prices is healthy. Growing almost entirely on price is a condition rather than a business model, and it reverses when supply catches up.
The practical step: find the volume line, or the price and mix line, in any results release. Companies that publish both are telling you something. Companies that publish neither may be telling you something too.
What could go wrong
- 💸 Prices are still falling, and that can accelerate. A 15% decline was comfortably absorbed by 53% volume growth. If volume growth slows while price pressure continues, the arithmetic reverses quickly.
- 🎁 About $900 million of this quarter was one-off. Milestones and favourable rebate adjustments flatter the comparison. The underlying quarter is still strong, but not by quite as much as the headline.
- 🧾 Acquisition charges are eating the earnings line. $4.57 a share of acquired research charges more than offset a $4.07 underlying improvement in guidance. Those charges reflect deals that may or may not pay off years from now.
- 🏁 Competition is intense and arriving. Rivals are launching their own treatments, including oral options, and Lilly itself is bringing a pill to market. Each new entrant adds price pressure, which is the dynamic our obesity-pill war post set out. And trial results move pharmaceutical shares violently: Moderna's cancer vaccine hit its endpoint and the stock fell 18%, because success was already priced in.
- 🏛️ Policy is a live risk. Drug pricing is politically contested in the United States and subject to negotiated listings elsewhere. A single policy decision can reset realised prices across a portfolio.
- 📈 Expectations are high. This is a company that has raised guidance repeatedly. The bar for the next quarter is set by this one.
LLY is an example to research, not a recommendation.
What should investors take from this?
The best kind of growth is the kind that survives falling prices.
When a company grows because more people want what it makes, that growth tends to persist. When it grows because it charged more for the same thing, the growth has a limit, and customers eventually find it.
Three habits:
- 🔍 Find the volume figure in any consumer or healthcare company's results, then compare it with revenue growth. The gap is price.
- 🎁 Strip out the one-offs. Milestones, rebate adjustments and currency effects can flatter a quarter. The company usually discloses them; most coverage skips them.
- ⚖️ Read earnings guidance and revenue guidance separately. Lilly raised revenue by $5.5 billion while earnings guidance moved differently because of acquisition charges. Both are true, and they describe different things, exactly as we found with Alphabet's three profit numbers.
And if you hold an index fund, you already own some of this. Eli Lilly is among the largest companies in the S&P 500, where the ten biggest holdings make up roughly 38% of the index. A quarter like this moves your fund whether or not you follow the company, which is why understanding what sits inside an index fund matters as much as choosing one.
It also means the volume-versus-price question is not only for people who pick individual shares. The companies driving your index are the ones whose pricing power decides its returns.
Research healthcare stocks on Nemo.money
- From $1. Fractional investing, in research-sized amounts.
- Zero commission on US stocks and ETFs.
- Nemes: curated themed collections to start from.
- 6% AER interest on uninvested cash, paid daily in USD.
FAQs
What did Eli Lilly report for Q3 2026? Revenue of $24.4 billion, up 39%, driven by a 53% increase in volume partially offset by a 15% decrease in realised prices. Mounjaro revenue rose 65% to $10.7 billion and Zepbound rose 48% to $5.4 billion. Adjusted earnings were $7.48 a share.
Did Eli Lilly raise its guidance? Yes. Full-year revenue guidance rose to $91-92 billion from $85-87 billion, an increase of $5.5 billion with a midpoint above the roughly $88.7 billion analysts expected. Adjusted earnings guidance is $35.00-36.00, reflecting $4.57 a share of acquired research charges that more than offset a $4.07 underlying improvement.
Why are Lilly's prices falling? The company reported a 15% decline in realised prices across the business, reflecting factors including rebates and discounts, government pricing arrangements and listing agreements in markets such as China. Revenue still grew 39% because volume rose 53%.
How much of the quarter was one-off? Lilly disclosed approximately $900 million of benefits in the quarter, primarily $410 million of Jardiance milestones alongside favourable adjustments to rebate and discount estimates.
Can I invest in Eli Lilly from the UAE? Eli Lilly trades on the New York Stock Exchange under the ticker LLY. On Nemo.money you can research and invest in eligible US-listed stocks and ETFs from $1 with zero commission, with uninvested cash earning 6% AER interest, paid daily in USD. LLY is an example to research, not a recommendation. Your capital is at risk.
Nemo = Never Miss Out.
Stay informed. Stay ahead.
#EliLilly #LLY #Healthcare #Earnings #StockMarket #Investing #NemoMoney
Terms and conditions apply. This is not investment advice and not medical advice. Past performance is not indicative of future results. Your capital is at risk. See website for Risk Disclosure. Exinity ME Ltd (https://nemo.money) is regulated by ADGM's Financial Services Regulatory Authority.
